The peripheral nervous system and the central nervous system (CNS) are comprised of assemblies of neurons that communicate via electrical and chemical signals. Different disease processes selectively affect specific populations of neurons and/or specific cell functions (i.e., "selective vulnerability" of neurons is a principal determinant of phenotypes of disease). New cellular and molecular biological approaches have begun to clarify some of the mechanisms of selective cell injury in human diseases and their animal models. Following a brief review of the normal biology of nerve cells, we use illustrations drawn from studies of experimental and human diseases to discuss the mechanisms of structurallchemical abnormalities that occur in a variety of neuronal disorders.
THE STRUC~URE AND FUNCTION OF NEURONS
Large motor neurons in the ventral horn give rise to myelinated axons that innervate skeletal muscle (89) . The geometry of these neurons reflects functional properties of specific regions of these cells. The nucleus contains DNA and the machinery for transcribing DNA into RNA; the cell body contains ribosomes that translate messenger RNA (mRNA) into newly synthesized proteins. Thus, the perikaryon is the principal site of protein synthesis in the neuron, and the axon and nerve terminals depend on the cell body for a continual supply of proteins. The axonal transport systems, distinguished on the basis ofdirection and rate of movement into fast, slow, and intermediate anterograde transport and retrograde transport, deliver macromolecules from one region of the neuron to another. Some of the proteins camed by these transport systems have been defined, and their functions have been clarified. For example, there are 3 neurofilament (NF) proteins cialized for generating and conducting action potentials. The synapse consists of a presynaptic terminal, synaptic cleft, and postsynaptic target cell (muscle), which maintains specific neurotransmitter receptors on its plasma membrane. When action potentials reach nerve terminals, Ca+ + permeability is increased locally, and the entry of Ca++ leads to fusion of acetylcholine-laden vesicles (quanta) at presynaptic active zones. Released by exocytosis, acetylcholine diffuses across the synaptic cleft and binds to receptors on the crests ofpostsynaptic folds. Interactions of transmitters with receptors initiate ion current flow in target cells. The resulting postsynaptic potential triggers an action potential, which is propagated along the muscle membrane, leading to changes in Ca++ that are, in turn, coupled to contraction.
RESPONSES OF NEURONS TO AXONAL INJURY
Axonal transection is one of the simplest models of neuronal injury (36, 41, 60, 62, 89, 97) . As a consequence of an acute focal interruption of fast anterograde and retrograde transport, the proximal and distal stumps of axons become enlarged with accumulated membranous elements (36). The distal stump undergoes Wallerian degeneration. Regenerating sprouts extend from the proximal stump along the basal lamina at rates of 1-3 mm/day, and, eventually, these axons reach targets, reinnervation occurs, and neurotransmission resumes. Neurons respond by structural alterations (e.g., chromatolysis, synaptic disjunction, etc.), by alterations in levels of specific mRNAs, and by changes in the synthesis and transport of specific proteins. Regenerating neurons selectively alter the transcription of certain mRNAs and the translation of certain proteins required in different stages of the cellular response (i.e., outgrowth, regeneration, restoration of caliber, and reinnervation). Fast transport delivers membranous constituents, particularly glycoproteins, required for growth cones and axolemma (35). The slow component transports tubulin for outgrowth and actin for motility of growth cones. The' amount of mRNA coding for N F proteins is reduced (40, 7 9 , and there is a parallel wave of*reduced axonal caliber that moves down the proximal part of the axon at a rate similar to that of the rate of transport of the N F proteins (41, 42). During the regenerative phase, markers for neurotransmitterrelated components are decreased (62) . When reinnervation occurs, constituents important for neurotransmission are synthesized and delivered to nerve terminals, the synthesis ofNFproteins returns to normal, and axonal caliber is restored (40, 42, 75).
ACUTE AND CHRONIC DISORDERS OF MOTOR NEURONS

Polioni yelitii
This viral disease selectively affects certain types of neurons (7, 50, 89) . In the paralytic form of the disease, the polio virus (single-stranded RNA) enters the host via the GI tract and eventually reaches the CNS. In motor neurons, the virus inhibits the synthesis of neuronal proteins, and these cells exhibit a variety of morphological and metabolic abnormalities. Eventually, injected neurons degenerate (7, 89) , and they are engulfed by phagocytic cells (neuronophagia). Skeletal muscles show neurogenic atrophy.
Aniyotrophic Lateral Sclerosis (ALS)
This progressive disorder involves both upper and lower motor neurons (12, 44, 104, 1 17, 118, 138) . In the majority of cases, the etiology is unknown (104, 118) . The disease appears to be inherited as an autosomal dominant in a relatively small percentage of adult cases (1 09). Clinical signs vary, depending on the degree of involvement of upper or lower motor neurons in spinal cord and brainstem: abnormalities of upper motor neurons include weakness, hyperreflexia, clonus, and extensor plantar responses; and manifestations of lower motor neuron disease include weakness, fasciculations, fibrillations, and muscle atrophy. A striking feature ofALS is the presence ofneurofilamentous swellings in proximal axons of motor neurons (12, 89) . Because NFs are carried by slow transport, the accumulation of maloriented NFs in proximal axons suggests that slow axonal transport may be abnormal in ALS (3 1, 37).
Alirniitiiun Intoxicatiori
Intrathecal injection of aluminum salts produces accumulations of NFs in cell bodies and proximal axons of certain populations of neurons, such as motor neurons in the spinal cord. The expression of genes coding for NF-L and tubulin is reduced by approxi.mately 3.5-fold and 3-fold, respectively, in the spinal cords of 'aluminum-intoxicated rabbits (76). Phosphorylated epitopes of NFs appear in the neurofibnllary masses in cell bodies and proximal axons of motor neurons (125, 126). It is not known whether phosphorylation in this abnormal location results because phosphorylation prevents NFs from entering axons or whether phosphorylation occurs secondary to the retention of NFs within perikarya. The number of NFs entering the axon is reduced, but the rate of transport of NFs is normal (6, 124) . TOXICOLOGIC PATHOLOGY
Iiitoxicatioti witit fi,fi'-itnitiodipropionitrile (IDPN)
IDPN produces a proximal neurofilamentous axonal pathology similar to that described in ALS (14, (32) (33) (34) . The toxin retards the movement of NF proteins (3 1,32). The mechanism of impairment is not yet completely understood, but IDPN may dissociate cytoskeletal microtubules from NFs, and failure of these interactions may underlie structural abnormalities that occur in axons (32). NF proteins continue to be synthesized in cell bodies and enter proximal axons, but they cannot be transported distally. Accumulation of NFs causes swellings of proximal axons and distal axonal atrophy. Similar processes may occur in ALS (3 1, 37) .
Hereditary Catlitre Spitial Miisailar Atrophy (HCSMA)
Hereditary canine spinal muscular atrophy (HCSMA) is a dominantly inherited motor neuron disease (105) that produces muscle weakness and atrophy in Brittany spaniels (16, 18, 20) as an autosomal dominant. Several phenotypic variants of the disease have been recognized (68); pups with accelerated disease are tetraplegic by 3-4 months of age; intermediately affected dogs become weak at approximately 6 months of age and are paralyzed at 2-3 yr of age; and chronically affected dogs show very mild weakness and little progression.
Ventral horns show neurofilamentous swellings in proximal axons (1 7) similar to those described in ALS (1 2). Analysis of predicted distributions ofcholinergic and noncholinergic neurons reveal that, in HCSMA, cholinergic neurons are smaller and that, in some size classes, fewer neurons express choline acetyltransferase. These observations indicate that motor neurons in affected dogs fail to achieve normal size (growth arrest) and/or undergo atrophy (1 6). There is impaired delivery of NF proteins and, to a lesser extent, tubulin. In the accelerated and intermediate phenotypes, axonal sizes in ventral roots are smaller than in controls. Reductions in axonal size occur primarily in large axons; the frequency of small-caliber axons is increased. The density of fibers in motor nerves is increased, making it unlikely that a selective loss of large-caliber axons accounts for the increased frequency of small-caliber axons. In concert, these observations suggest that, in HCSMA, changes in axonal size in motor nerves are associated with both growth arrest and axonal atrophy (20).
Botulism
Botulinum toxin, produced by Clostridiutn botidinwn, causes fatal neuromuscular paralysis (52, 1 10, 1 1 1, 123). The toxin, synthesized as a singlc chain, has a molecular weight of 150 kiloDaltons (kD); the parent molecule is cleaved to form the active diachain peptide (100 kD and 50 kD) (1 10). Three steps appear to be necessary for toxicity: binding of toxin to neuronal membranes on synaptic terminals; entry of toxin perhaps by channel formation; and intracellular toxicity. The outcome of these presynaptic events into the nerve terminals is a significant reduction in the release of acetylcholine from cholinergic nerve endings (52) . Failure of neurotransmission is the basis for neuromuscular paralysis. The specific mechanisms whereby botulinum toxin blocks synaptic transmission remain to be elucidated (I 1 1, 123).
Tetattiis
Tetanus results when tetanospasmin (1 50 kD), a toxin produced in contaminated wounds by Clostridiuni tetatii, reaches the CNS, where it interferes with inhibitory synaptic transmission with spinal cord and brainstem (87, 127, 134) . This toxin, coded for by a sequence on a plasmid (24), is composed of 2 nonidentical polypeptide chains-a heavy chain of approximately 100 kD and a light chain of 50 kD (1 10). The presence of a blood-brain barrier prevents the polypeptide from direct entry into the CNS.
Locally produced and systemically circulating toxin diffuses through the internal spaces in muscle; the carboxy terminal of the heavy chain binds to ganglioside-containing receptors on membranes of nerve terminals. The toxin is taken up into these terminals by receptor-mediated endocytosis and is carried by retrograde axonal transport to motor neurons (13, 88, 91, 92) . Once the toxin reaches neurons in the brainstem and spinal cord, it passes transsynaptically to bind to synaptic terminals located on penkarya of these nerve cells (90) . Many of these axosomatic and proximal axodendritic inputs are inhibitory and use glycine as a neurotransmitter (98). Tetanus toxin acts presynaptically on these terminals and prevents the release of glycine (87) . With the removal of these inhibitory inputs, excitation is unapposed, and the result is tetanus,
PARKINSONISM Parkinsottk Disease (PO)
PD, an adult-onset disorder of unknown etiology (IOS), is characterized by bradykinesia, rigidity, resting tremor, and stooped posture (49, 72, 99) . Motor abnormalities in PD are associated with loss of pigmented dopaminergic neurons in the substantia nigra pars compacta (SNpc) (47) . These cells commonly contain intracytoplasmic Lewy bodies (25) that represent, in part, accumulations of phosphorylated epitopes of neurofilaments (29). Abnormalities of the nigrostriatal system are associated Vol. 18, No. 1 (Part 2), 1990 DISEASES OF NEURONS IN HUMANS AND ANIMAL MODELS 13 1 with marked depletions of presynaptic dopaminergic markers in the striatum (1 1, 43) .
Intoxication with Imethyl-4-plietiyl-
1,2,3,6, tet raii ydropyridir ie (MPTP) in Monkeys
Monkeys systemically treated with MPTP exhibit bradykinesia, rigidity, and low-amplitude resting tremor (10, 63) . Circulating MPTP gains access to brain; it binds to monoamine oxidase B, an enzyme enriched in certain regions in the CNS, including the striatum (78), and is converted to I-methyl-4phenylpyridinium (MPPi-). This toxic metabolite (66) is taken up by high-affinity dopamine uptake systems located on terminals of nerve cells of the SNpc (46) . These inhibitors of monoamine oxidase B activity and dopamine uptake can block the neurotoxic effects of MPTP (46, 63, 66) . At low-dose levels, many cells in the SNpc show evidence of injury, particularly in axons and/or terminal fields as revealed by reduced dopaminergic markers and tyrosine hydroxylase (TH) immunoreactivity in striatum (10, 57, 63, 65) . Many SNpc cells are virtually devoid of TH immunoreactivity. Some of the peripheral abnormalities appear to be secondary to axonal injury, a concept consistent with studies of other neuronal systems in which axotomy results in reductions in amounts of neurotransmitter and/or transmitter-synthesizing enzymes (60, 62) . Surviving TH-negative nigral neurons may eventually reconstitute their axons, establish contact with their targets, and manufacture and deliver TH to terminals in the striatum.
The MPTP model of parkinsonism provides an experimental preparation in which to examine how abnormalities of specific populations of neurons contribute to disorders of movement and to test therapeutic approaches, including new pharmacotherapies and neuronal grafts (loo), to restore function of damaged circuits in the basal ganglia.
ALZHEIMER'S DISEASE Neuronal Systenis Afected in Alzheiriier 's Disease (AD)
Cholinergic neurons in the basal forebrain magnocellular complex are affected in virtually all cases ofAD. These cells show neurofibrillary tangles (NFT) (I 37), and their distal axons/nerve terminals contribute neurites to some senile plaques (1) . Cholinergic markers are reduced in target fields (8, 26, 53, 82, 136) .
In some cases of AD, degeneration occurs in noradrenergic neurons of the locus coeruleus. Noradrenergic axons and terminals may form neurites in plaques (84). Reductions in numbers of neurons of the locus coeruleus may be related to the presence of depression in AD (103, 144) Pyramidal neurons in hippocampus and in entorhinal cortex develop NFT (4, 45, 54) ; eventually, many of thesc neurons degenerate. The neocortex shows NFT, neuronal atrophy, and reductions in numbers of neurons (54, 67, 122) . Pyramidal neurons are severely affected (67, 74) as are cortical neurons that utilize corticotropin-releasing factor (CRF) or somatostatin as transmitters (21,22, 102). These peptidergic neurons develop NFT, and their axons/dendrites/terminals contribute neurites to plaques (2, 85, 1 15) . Somatostatin receptors are reduced (9, but CRF receptors are increased (22).
Abnor),ialities of the Neirrorial Cytoskeletoti
NFT and the fibrillary elements in neurites of plaques are composed of accumulations of paired helical filaments (PHF) and straight filaments (15 nm in diameter) (55, 79, 81). NFT and neurites express a number of antigens, including: tau; A68; microtubule-associated protein 2; phosphorylated 200-kD polypcptidc neurofilament subunit; ubiquitin; and, probably, @/A4 (9, 19, 27, 30, 38, 48, 69, 71,73,79-81, 139, 140, 142) .Aftercelldeath, these filamentous aggregates persist as extracellular "ghosts" or "tombstones" (64, 121, 141) .
Aniyloid Precursor Protein (APP) aiid A niyloidogenesis
Extracellular amyloid fibrils, composed primarily of @/A4 are localized in plaques and around blood vessels (71, 95, 106, 107, 143). @/A4 is a truncated form of APP, a membrane-spanning glycoprotein (23,133) encoded by a gene located on chromosome 21 (28, 51, 101, 119). The APP gene has at least three differentially spliced mRNAs that encode: APP-695, without protease inhibitor domains (5 1); and APP-751 and APP-770, with inserted sequences similar to those identified in Kunitz-type protease inhibitors (56, 83, 120) . APP mRNAs with the inhibitor domain are expressed in many tissues, including brain (56,83, 120), whereas APP-695 appears to be expressed predominantly in brain (83).
The APP gene is actively transcribed by neurons in manyiegions (3, ! 5, 39, 6 1, 62, 77). APP-like immunoreactivity is present in neurons of the brains of macaques. For example, APP-enriched neurons were found predominantly in layers I11 and V of neocortex (70, 133) . APP is present in axons, where it is transported by the fast anterograde system.
Aged Non-hirnian Primates
As compared to young controls, aged non-human primates are impaired in performance on memory tasks involving visual recognition, spatial learning, TOXICOLOGIC PATHOLOGY habit formation, and visuospatial manipulations (86, 132). These macaques also show some of the neuropathological features (senile plaques, congophilic angiopathy, and, infrequently, NFT) that occur in some aged humans as well as all subjects with AD (106, 129). At the end of the second decade of life, some of these animals show axonal abnormalities (58, 59, 112, 114, 116, (130) (131) (132) . Some of these abnormal axons/nerve terminals form neurites in plaques (1 13, 1 16, 130, 132) . Neurites in plaques are derived from multiple transmitter-specific systems (58, 59, 116, 129, 131) , and neurites in an individual plaque may be derived from more than one transmitter-specific population (1 29). Levels of some presynaptic markers and receptors decline with age (128, 135).
Levels of APP mRNA in various brain regions do not change with age (62) (ix., levels of total APP gene expression do not directly correlate with the presence of cerebral amyloid). In non-human primates, the formation of neuntes appears to precede the deposition of amyloid (1 16). APP-like immunoreactivity is present in some neurites of plaques (70) , and some of these neurites are capped by deposits of /3/A4. These observations suggest that one source of B/A4 may be derived from neuronal APP (which is transported to neurites where it is abnormally processed to form deposits of @/A4 in the parenchyma of brain (70, 93, 94) .
CONCLUSION
Neuropathological investigations of human neurological disorders show that specific populations of neurons and/or specific cell functions are selectively affected in different disorders and that these specific abnormalities are the major determinants of disease phenotypes. The mechanisms that lead to structural and chemical abnormalities of neurons are being clarified by cellular/molecular studies of human diseases and their experimental models. 
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